These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2118328)

  • 1. Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.
    Parent M; St-Laurent M; LeBel M
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1249-53. PubMed ID: 2118328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of lomefloxacin on the pharmacokinetics of theophylline.
    LeBel M; Vallée F; St-Laurent M
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1254-6. PubMed ID: 2393286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
    Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and multiple dose pharmacokinetics of fleroxacin.
    Weidekamm E; Portmann R; Partos C; Dell D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered disposition of fleroxacin in patients with cystic fibrosis.
    Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
    Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
    Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E
    Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal tolerance of fleroxacin in healthy volunteers.
    Mondorf AW; Buch A; Steinbacher G; Rüdel C; Falkenberg FW
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():179-89. PubMed ID: 2904925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.
    Wolfhagen MJ; Hoepelman AI; Verhoef J
    Antimicrob Agents Chemother; 1990 Mar; 34(3):409-12. PubMed ID: 2110437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.
    Bowie WR; Willetts V; Jewesson PJ
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1778-82. PubMed ID: 2511802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.
    Panneton AC; Bergeron MG; LeBel M
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1515-20. PubMed ID: 3142338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.
    Shah PM; Sammann A; Schäfer V; Seczendi M; Knothe H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():209-13. PubMed ID: 3144539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
    Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of fleroxacin in man.
    Sörgel F; Seelmann R; Naber K; Metz R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
    Weidekamm E; Portmann R; Suter K; Partos C; Dell D; Lücker PW
    Antimicrob Agents Chemother; 1987 Dec; 31(12):1909-14. PubMed ID: 3125788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
    Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
    Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
    Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections.
    Frankenschmidt A; Naber KG; Bischoff W; Kullmann K
    J Urol; 1997 Oct; 158(4):1494-9. PubMed ID: 9302150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.
    Stuck AE; Frey FJ; Heizmann P; Brandt R; Weidekamm E
    Antimicrob Agents Chemother; 1989 Mar; 33(3):373-81. PubMed ID: 2499248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complicated urinary infection in spinal injury patients: fleroxacin compared with ciprofloxacin.
    Whitby M; Angus L; Nimmo G; Hill V
    Chemotherapy; 1996; 42(6):468-72. PubMed ID: 8957583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue.
    Kees F; Naber KG; Schumacher H; Grobecker H
    Chemotherapy; 1988; 34(6):437-43. PubMed ID: 2468456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.